Inhibiting integrin αvβ3 signaling not only enhances radiotherapy efficacy [25,26] but also promotes lung cancer progression via the FAK/AKT/SOX2 pathway, as demonstrated by Zhou et al. [27]. This evidence concerns the gene AKT1 and lung cancer.